You are here

skin infection

FDA Approves Durata Therapeutics' DALVANCE(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Susceptible Gram-Positive Bacteria, Including MRSA, in Adults

Yahoo/Globe Newswire

Sat, 05/24/14 - 09:44 am

Durata Therapeutics

Two IPOs Brave the Markets, Two Enter the Queue: Biotech's Latest Deals

Seeking Alpha

Sun, 08/8/10 - 01:18 pm

Trius Therapeutics

Complete Genomics

Trius Gets SPA From FDA For Torezolid Phosphate Phase 3 Study

Pharmaceutical Business Review

Thu, 06/17/10 - 09:53 am

Trius Therapeutics

Novexel Starts Phase II Clinical Trial With NXL103 In Adults With Acute Bacterial Skin And Skin Structure Infections (ABSSSI)

prnewschannel.com

Sun, 11/8/09 - 12:39 pm